First patient treated in the EffiKIR trial
MARSEILLE, France I December 17, 2012 I Innate Pharma SA, the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the first patient was treated in the EffiKIR trial.
A trial has begun for Jonathon Hope and Lisa Hope in the overdose death of their 16-month-old daughter in 2006.